Compare D R Horton Inc (DHI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Novavax Inc — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: D R Horton Inc is far larger — about 20.9× Novavax Inc's market cap, and D R Horton Inc pays a 1.33% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Novavax Inc for 59 Days on average.
| DHI | NVAX | |
|---|---|---|
Market Cap | $37.99B | $1.82B |
Volume | 2,974,460 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $12.75 |
52-Week Low | $132.53 | $6.22 |
Typical Hold Time | 46 Days | 59 Days |
Enterprise Value | $43.09B | $1.39B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $135.82, up 1.91% with a bearish technical signal despite recent earnings beats. The stock faces headwinds from rising mortgage rates impacting the housing sector, with revenue declining to $34.25B in 2025 and net income margin compressing to 9.15%. Analyst consensus remains positive with a $156.57 price target, but technical indicators show resistance at $137 with support at $133.
The outlook is mixed with strong fundamentals and attractive valuation (P/E 12.95) offset by macroeconomic pressures on housing demand. Key risks include persistent high interest rates and housing market volatility, while institutional sentiment leans bullish with 47% buy ratings. The stock offers value for long-term investors but faces near-term sector headwinds.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
